Qbtech announced that its remote testing solution QbCheck, improves ADHD diagnosis and treatment by enhancing patient outcomes, based on findings from a clinical study.
The study, conducted with ADHD 360, the UK’s largest evidence-based digital service for ADHD, shows how QbCheck helps clinicians make more confident, data-informed decisions.
It highlights QbCheck’s role in providing clarity when assessing symptoms and adjusting treatment plans over time, ensuring diagnostic accuracy and strengthening the care journey.
ADHD 360 implemented the model for a standardised approach to virtual ADHD care, which boosts clinician confidence, reduces wait times, and enhances patient engagement.
Beyond its diagnostic capabilities, QbCheck also monitors treatment effects, allowing clinicians to adjust treatment as necessary.
The study showed significant improvements from baseline to post-treatment assessments.
It highlights patient response to pharmacological treatment, aiding clinicians in developing individualised and adaptive treatment plans, providing quantifiable data on symptom presentation and response.
ADHD 360 mental health nurse and team manager Carl Ellis said: “Consistency and quality are at the heart of our virtual care model, and QbCheck plays a key role in upholding these standards.
“The objective data it provides ensures that every patient is assessed using the same evidence-based criteria, regardless of where they are.
“Not only does this minimise the risk of subjective bias, but it also ensures that our clinical team can deliver reliable, high-quality care at scale.”
Data for the study were collected from routine QbCheck assessments conducted as part of the ADHD 360 model in the UK.
Baseline data was gathered before diagnosis and treatment, with further QbCheck assessments administered after patients were optimised with stimulant medication.
Patients were also given the Adult ADHD Self Report Scale (ASRS) or the Swanson, Nolan and Pelham Rating Scale (SNAP) and QbCheck Rating Scale (QbRS) to assess symptoms.
With growing scrutiny around ADHD care and the expansion of virtual care models, QbCheck stands out for its clinical rigour, patient-centred design, and scalability.
First developed in 2016, QbCheck enriches the clinician and patient experience, ensuring optimal care in virtual settings.
It is used by more than 10,000 clinicians worldwide, providing equitable access to care regardless of location since its launch in Sweden in 2002.
Qbtech chief medical officer Mikkel Hansen said: “QbCheck brings transparency and structure to the process, enabling clinicians to clearly visualise symptoms, track treatment response, and give patients the objective validation they deserve.
“This data shows how a standardised pathway to virtual ADHD care helps clinicians successfully facilitate remote monitoring of medication treatment effects, symptom regulation, and overall treatment outcomes, which are essential to virtual care models like ADHD 360.”
